What Happens During the First Week of Semaglutide?
The first week of Semaglutide treatment is primarily an adjustment phase. Most people begin with a low introductory dose, commonly 0.25 mg weekly, allowing the body to gradually adapt to GLP-1 receptor stimulation.
Early changes are often related to appetite regulation rather than dramatic fat loss. Many users report feeling full faster, thinking less about food, or noticing reduced cravings within several days.
- Reduced appetite
- Smaller meal portions
- Mild nausea
- Earlier satiety
- Water weight fluctuations
- Lower snacking frequency
First Week Timeline
Initial Adjustment Phase
Appetite may begin decreasing slightly, although some users notice little change immediately after the first injection.
Early Appetite Changes
Many users report feeling fuller faster, eating smaller portions, and experiencing reduced cravings.
Digestive Adaptation
Mild gastrointestinal effects such as bloating, nausea, or constipation may appear during adjustment.
End of Week Overview
Some users notice small scale changes, mostly from lower calorie intake and water fluctuations.
Expected Weight Loss During Week 1
Significant fat loss is uncommon during the first week, but small scale changes may occur due to:
- Reduced calorie intake
- Lower carbohydrate consumption
- Decreased water retention
- Reduced snacking frequency
| Week 1 Change | Common Observation |
|---|---|
| Appetite | Usually reduced |
| Meal Size | Often smaller |
| Body Weight | Minor fluctuations possible |
| Energy Levels | Can temporarily fluctuate |
| Cravings | May decrease |
Common Week 1 Side Effects
Gastrointestinal symptoms are most common during the early adaptation phase. Symptoms are often mild and improve over time.
- Nausea
- Bloating
- Constipation
- Diarrhea
- Reduced appetite
- Temporary fatigue
Starting with low doses helps improve tolerability during the first several weeks.
Compare Semaglutide Treatment Programs
Explore provider pricing, dosage plans, telehealth consultations, and beginner-friendly GLP-1 programs.